The anti-HIV activity of ADS-J1 targets the HIV-1 gp120

Virology

Volumn 343, Issue 1, 2005, Pages 141-149

  Armand Ugón, Mercedes ^a   Clotet Codina, Imma ^a   Tintori, Cristina ^b   Manetti, Fabrizio ^b   Clotet, Bonaventura ^a   Botta, Maurizio ^b   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Drug resistance; Entry; Fusion; gp120; gp41; HIV 1

Indexed keywords

ADS J1; ANTIVIRUS AGENT; C 34; DEXTRAN SULFATE; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; POLYANION; PROTEIN INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN; ZIDOVUDINE; ZINTEVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION, MISSENSE; NAPHTHALENESULFONATES; PEPTIDE FRAGMENTS; POLYMERS; PROTEIN BINDING; T-LYMPHOCYTES; TRIAZINES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 27644505400     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.08.007     Document Type: Article

References (33)

1. M. Armand-Ugon, A. Gutierrez, B. Clotet, and J.A. Este HIV-1 resistance to the gp41-dependent fusion inhibitor C-34 Antiviral. Res. 59 2 2003 137 142
2. M. Armand-Ugon, M.E. Quinones-Mateu, A. Gutierez, J. Barretina, J. Blanco, D. Schols, E. De Clercq, B. Clotet, and J.A. Este Reduced fitness of HIV-1 resistant to CXCR4 antagonists Antiviral Ther. 8 1 2003 1 8
3. J. Barretina, J. Blanco, M. Armand-Ugon, A. Gutierrez, B. Clotet, and J.A. Este Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death Antiviral Ther. 8 2 2003 155 161
4. J. Barretina, J. Blanco, A. Bonjoch, A. Llano, B. Clotet, and J.A. Este Immunological and virological study of enfuvirtide-treated HIV-positive patients AIDS 18 12 2004 1673 1682
5. D. Batinic, and F.A. Robey The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides J. Biol. Chem. 267 10 1992 6664 6671
6. E.A. Berger, R.W. Doms, E.M. Fenyo, B.T. Korber, D.R. Littman, J.P. Moore, Q.J. Sattentau, H. Schuitemaker, J. Sodroski, and R.A. Weiss A new classification for HIV-1 Nature 391 6664 1998 240
7. J. Blanco, J. Barretina, K.F. Ferri, E. Jacotot, A. Gutierrez, M. Armand-Ugon, C. Cabrera, G. Kroemer, B. Clotet, and J.A. Este Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events Virology 305 2 2003 318 329
8. J. Blanco, J. Barretina, B. Clotet, and J.A. Este R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism J. Leukocyte Biol 76 4 2004 804 811
9. M.D. Bobardt, M. Armand-Ugon, I. Clotet, Z. Zhang, G. David, J.A. Este, and P.A. Gallay Effect of polyanion-resistance on HIV-1 infection Virology 325 2 2004 389 398
10. D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 2 1997 263 273
11. W. Chen, Z. Tang, P. Fortina, P. Patel, S. Addya, S. Surrey, E.A. Acheampong, M. Mukhtar, and R.J. Pomerantz Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways Virology 334 1 2005 59 73
12. A.K. Debnath, L. Radigan, and S. Jiang Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1 J. Med. Chem. 42 17 1999 3203 3209
13. G.A. Donzella, D. Schols, S.W. Lin, J.A. Esté, K.A. Nagashima, P.J. Maddon, G.P. Allaway, T.P. Sakmar, G. Henson, E. De Clercq, and J.P. Moore AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor Nat. Med. 4 1 1998 72 77
14. J.A. Este Virus entry as a target for anti-HIV intervention Curr. Med. Chem. 10 17 2003 1617 1632
15. J.A. Este, D. Schols, K. De Vreese, K. Van Laethem, A.M. Vandamme, J. Desmyter, and E. De Clercq Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein Mol. Pharmacol. 52 1 1997 98 104
16. J.A. Este, C. Cabrera, D. Schols, P. Cherepanov, A. Gutierrez, M. Witvrouw, C. Pannecouque, Z. Debyser, R.F. Rando, B. Clotet, J. Desmyter, and E. De Clercq Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir) Mol. Pharmacol. 53 2 1998 340 345
17. J.A. Este, C. Cabrera, J. Blanco, A. Gutierrez, G. Bridger, G. Henson, B. Clotet, D. Schols, and E. De Clercq Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4 J. Virol. 73 7 1999 5577 5585
18. V. Fikkert, P. Cherepanov, K. Van Laethem, A. Hantson, B. Van Remoortel, C. Pannecouque, E. De Clercq, Z. Debyser, A.M. Vandamme, and M. Witvrouw Env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors Antimicrob. Agents Chemother. 46 12 2002 3954 3962
19. N.G. Hoffman, F. Seillier-Moiseiwitsch, J. Ahn, J.M. Walker, and R. Swanstrom Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop J. Virol. 76 8 2002 3852 3864
20. S. Jiang, and A.K. Debnath A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity Biochem. Biophys. Res. Commun. 270 1 2000 153 157
21. S. Jiang, H. Lu, S. Liu, Q. Zhao, Y. He, and A.K. Debnath N-substituted pyrrole derivatives as novel human immunodeficiency virus Type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 48 11 2004 4349 4359
22. J.M. Kilby, S. Hopkins, T.M. Venetta, B. DiMassimo, G.A. Cloud, J.Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M.R. Johnson, M.A. Nowak, G.M. Shaw, and M.S. Saag Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat. Med. 4 11 1998 1302 1307
23. M. Kowalski, J. Potz, L. Basiripour, T. Dorfman, W.C. Goh, E. Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1 Science 237 4820 1987 1351 1355
24. J.P. Lalezari, K. Henry, M. O'Hearn, J.S. Montaner, P.J. Piliero, B. Trottier, S. Walmsley, C. Cohen, D.R. Kuritzkes, J.J. Eron Jr., J. Chung, R. DeMasi, L. Donatacci, C. Drobnes, J. Delehanty, and M. Salgo Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America N. Engl. J. Med. 13 2003 13
25. A. Lazzarin, B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H.J. Stellbrink, J.F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drobnes, and M. Salgo Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia N. Engl. J. Med. 348 22 2003 2186 2195
26. L. Menendez-Arias, and J.A. Este HIV-resistance to viral entry inhibitors Curr. Pharm. Des. 10 15 2004 1845 1860
27. M. Moulard, H. Lortat-Jacob, I. Mondor, G. Roca, R. Wyatt, J. Sodroski, L. Zhao, W. Olson, P.D. Kwong, and Q.J. Sattentau Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120 J. Virol. 74 4 2000 1948 1960
28. C. Notredame, D.G. Higgins, and J. Heringa T-Coffee: a novel method for fast and accurate multiple sequence alignment J. Mol. Biol. 302 1 2000 205 217
29. J.O. Ojwang, R.W. Buckheit, Y. Pommier, A. Mazumder, K. De Vreese, J.A. Esté, D. Reymen, L.A. Pallansch, C. Lackman-Smith, T.L. Wallace, E. De Clercq, M.S. McGrath, and R. Rando T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 39 11 1995 2426 2435
30. J.O. Ojwang, R.W. Buckheit, Y. Pommier, A. Mazumder, K. De Vreese, J.A. Este, D. Reymen, L.A. Pallansch, C. Lackman-Smith, and T.L. Wallace T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 39 11 1995 2426 2435
31. G. Pollakis, S. Kang, A. Kliphuis, M.I. Chalaby, J. Goudsmit, and W.A. Paxton N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization J. Biol. Chem. 276 16 2001 13433 13441
32. R.R. Vives, A. Imberty, Q.J. Sattentau, and H. Lortat-Jacob Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site J. Biol. Chem. 280 22 2005 21353 21357
33. R. Wyatt, and J. Sodroski The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens Science 280 5371 1998 1884 1888